Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CSF1R |
| Variant | Y571D |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | CSF1R Y571D lies within the regulatory juxtamembrane domain of the Csf1r protein (UniProt.org). Y571D was shown to result in constitutive activation of the Csf1r protein, increased colony growth, and elevated Csf1r signaling in cultured cells (PMID: 18971950). |
| Associated Drug Resistance | |
| Category Variants Paths |
CSF1R mutant CSF1R act mut CSF1R Y571D |
| Transcript | NM_001288705.3 |
| gDNA | chr5:g.150061765A>C |
| cDNA | c.1711T>G |
| Protein | p.Y571D |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_005211.4 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_001288705 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_001375320.1 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_001288705.2 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_001349736.1 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_005211.3 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_001349736.2 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_001288705.3 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| NM_005211 | chr5:g.150061765A>C | c.1711T>G | p.Y571D | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF1R mutant | Erdheim-Chester disease | sensitive | Pexidartinib | Guideline | Actionable | Turalio (pexidartinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring CSF1R mutations (NCCN.org). | detail... |